Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Aug 2023

Woyach Jennifer A, Ghia Paolo, Byrd John C, Ahn Inhye E, Moreno Carol, O'Brien Susan M, Jones Daniel, Cheung Leo W K, Chong Elizabeth, Kwei Kevin, Dean James P, James Danelle F, Wiestner Adrian

Abstract excerpt

PURPOSE: Acquired mutations in Bruton's tyrosine kinase (BTK) or phospholipase C-γ2 (PLCG2) genes are associated with clinical progressive disease (PD) in patients with chronic lymphocytic leukemia (CLL) treated with BTK inhibitors. Data on mutation rates in patients without PD on ibrutinib treatment are limited. EXPERIMENTAL DESIGN: We evaluated frequency and time to detection of BTK and PLCG2 mutations in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Agammaglobulinaemia Tyrosine Kinase
Share to Leukemia, Lymphocytic, Chronic, B-Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Receptors, Antigen, B-Cell

Source

Open in PubMed Open full text

Identifiers

PMID: 37314786
DOI: 10.1158/1078-0432.CCR-22-3887
PMCID: PMC10425728

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy.PMID 37314786Read ↗

Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?Semantic proximity Read ↗

Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax.Semantic proximity Read ↗

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinibSemantic proximity Read ↗

Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib.Semantic proximity Read ↗

PLCG2 exon-skipped variants: insights into their potential role in chronic lymphocytic leukemia.Semantic proximity Read ↗

Resistance-Associated Mutations in Chronic Lymphocytic Leukemia Patients Treated With Novel AgentsSemantic proximity Read ↗

Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia.Semantic proximity Read ↗

Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy.Semantic proximity Read ↗

Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE studySemantic proximity Read ↗

Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor–resistant chronic lymphocytic leukemia with disease progression and Richter transformationSemantic proximity Read ↗

Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia.Semantic proximity Read ↗

Pirtobrutinib at the Crossroads: Shaping Its Future Role in Chronic Lymphocytic Leukemia (CLL) Care.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.